These findings support the use of 14-3-3 and total tau as CSF biomarkers in classical scrapie and suggest that the underlying neurodegenerative mechanisms that release these proteins to the CSF also occur in the early stages of neurodegeneration, therefore pointing at them as possible biomarkers for the preclinical stages of prion disease. This evidence concerns the gene MAPT and prion disease.